4.4 Article

Patients' knowledge and fear of colorectal cancer risk in inflammatory bowel disease

期刊

JOURNAL OF DIGESTIVE DISEASES
卷 17, 期 6, 页码 383-391

出版社

WILEY-BLACKWELL
DOI: 10.1111/1751-2980.12356

关键词

colorectal cancer; Crohn disease; fear; inflammatory bowel disease; knowledge; ulcerative colitis

资金

  1. Vifor Pharma
  2. Merck
  3. Abbvie
  4. Janssen
  5. Genentech
  6. Mitsubishi
  7. Ferring
  8. Norgine
  9. Tillots
  10. Vifor
  11. Therakos
  12. Pharmacosmos
  13. Pilege
  14. BMS
  15. UCB-pharma
  16. Hospira
  17. Celltrion
  18. Takeda
  19. Biogaran
  20. Boerhinger-Ingelheim
  21. Lilly
  22. Pfizer
  23. HAC-Pharma
  24. Index Pharmaceuticals
  25. Amgen
  26. Sandoz
  27. Forward Pharma GmbH
  28. Celgene

向作者/读者索取更多资源

OBJECTIVE: To investigate knowledge and fear of colorectal cancer (CRC) risk in inflammatory bowel disease (IBD) patients. METHODS: A 12-item self-administered questionnaire, developed after a careful literature review, was administered to all consecutive IBD patients treated with infliximab who were followed up at Nancy University Hospital (Vandoeuvre-les-Nancy, France) between February and May 2012. RESULTS: Altogether 100 patients including 72 with Crohn's disease (CD) were included. Only 7.0% of patients spontaneously mentioned CRC risk as a main feature of IBD and 37.0% as a potential IBD complication. CRC was the most feared complication by 26 patients [ulcerative colitis (UC) 46.4% vs CD18.1%, P < 0.01]. Two-thirds of patients knew that IBD increases CRC risk (UC 81.9% vs CD 57.1%, P = 0.02). Their main source of information was their gastroenterologist (52.0%). On the best screening method for CRC, 86.0% of the respondents mentioned colonoscopy. Only 32.0% of patients knew that it has to be performed 10 years after diagnosis. In case of dysplasia, 51.0% of the patients would not undergo colectomy (CD 59.7% vs UC 28.6%, P < 0.01), mainly due to the fear of having ostomy bags. Only one-quarter of UC patients were aware of the chemopreventive effect of 5-aminosalicylates on CRC risk. CONCLUSIONS: Two-thirds of IBD patients are aware of the risk of CRC. UC patients have a better knowledge of this risk and are more afraid of this complication. Our results underscore the need for therapeutic education about CRC in IBD patients.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据